SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 99,000
+4,200 (4.43%)
At close: Apr 1, 2026
SK Biopharmaceuticals Revenue
In the year 2025, SK Biopharmaceuticals had annual revenue of 706.74B KRW with 29.06% growth. SK Biopharmaceuticals had revenue of 194.36B in the quarter ending December 31, 2025, with 19.22% growth.
Revenue
706.74B
Revenue Growth
+29.06%
P/S Ratio
10.97
Revenue / Employee
2.87B
Employees
246
Market Cap
7.75T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 706.74B | 159.14B | 29.06% |
| Dec 31, 2024 | 547.60B | 192.70B | 54.30% |
| Dec 31, 2023 | 354.89B | 108.71B | 44.16% |
| Dec 31, 2022 | 246.18B | -172.47B | -41.20% |
| Dec 31, 2021 | 418.64B | 392.65B | 1,510.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 3.02T |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| OliX Pharmaceuticals | 14.67B |